1st Mar 2006 09:07
Stem Cell Sciences plc01 March 2006 For Immediate Release 1 March 2006 Stem Cell Sciences plc Notice of Preliminary Results Stem Cell Sciences plc, the global stem cell company focused on the application of stem cell technologies to cell culture media, cell based drug screens and novel cell therapies, will be announcing its preliminary results for the year ended 31 December 2005 on Thursday 30 March 2006. - Ends - For further information please contact: Weber Shandwick Square Mile 020 7067 0725Yvonne Alexander Notes to Editor Stem Cell Sciences plc (SCS) is a global biotechnology company focused on thedevelopment of stem cell technologies. The Company has established a leadingintellectual property (IP) and technology portfolio that enables the commercialapplication of stem cells in pharmaceutical and biotechnology drug discovery,providing the Company with an early-stage revenue stream. In the longer term,the Company is developing regenerative, cell-based therapies. Stem Cell Sciences has four business units focused on key sustainable businessstrategies. SC Proven provides serum free, cell culture media and reagents thatenable the growth of stem cells. The first commercially available product, amouse embryonic stem cell growth medium, has been exclusively licensed formanufacture and marketing to Chemicon, a division of Serologicals Inc. SCLicensing licenses its proprietary technologies such as Internal Ribosome EntrySite (IRES) and Stem Cell Selection for application in laboratory-based researchand discovery. SC Services will provide cell production for research andhigh-throughput drug screening. SC Therapies first program is being undertakenby SCS's Japanese affiliate, which recently announced the exclusive licensing ofhuman multipotent adipocyte-derived (hMADS) for use in an experimental cellbased therapy programme against Duchene's Muscular Dystrophy form the basis fora degenerative diseases focused pre-clinical programme. SCS plc is a global Group with operations in the UK, Australia and Japan. Eachcompany is affiliated with academic stem cell centres of excellence in order toaccess and commercialize new IP developing in the field. These include theInstitute of Stem Cell Research, Edinburgh, UK; RIKEN Centre for DevelopmentBiology, Japan and the Australian Stem Cell Centre, Melbourne, Australia. SCS, which listed on the London Alternative Investment Market in July 2005, wasfounded in 1994 to commercialize findings from the Institute of Stem CellResearch at the University of Edinburgh, UK, and Monash University, Melbourne,Australia. The Company is a participant in two research projects under theEuropean Union's Framework Six Programme for Research and Technology Developmentand is a contributor to the UK Stem Cells Initiative. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree